Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luisa Guidi

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2010
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel diseaseMario Cottone, Anna Kohn, Marco Daperno, et al.
United European Gastroenterology Journal|May 23, 2020
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centreFranco Scaldaferri, Daniela Pugliese, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|June 4, 2018
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre StudyLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|March 6, 2012
[Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data]Pietro Manuel Ferraro, Valeria D'Ovidio, Giampaolo Bresci, et al.
Journal of Clinical Apheresis|November 11, 2011
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric studyStefano Passalacqua, Pietro Manuel Ferraro, Giampaolo Bresci, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Cancers|February 15, 2022
Incident Colorectal Cancer in Inflammatory Bowel DiseaseBenedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|January 17, 2017
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab BiosimilarGionata Fiorino, Natalia Manetti, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|September 10, 2019
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2010
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel diseaseMario Cottone, Anna Kohn, Marco Daperno, et al.
United European Gastroenterology Journal|May 23, 2020
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centreFranco Scaldaferri, Daniela Pugliese, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|June 4, 2018
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre StudyLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|March 6, 2012
[Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data]Pietro Manuel Ferraro, Valeria D'Ovidio, Giampaolo Bresci, et al.
Journal of Clinical Apheresis|November 11, 2011
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric studyStefano Passalacqua, Pietro Manuel Ferraro, Giampaolo Bresci, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Cancers|February 15, 2022
Incident Colorectal Cancer in Inflammatory Bowel DiseaseBenedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|January 17, 2017
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab BiosimilarGionata Fiorino, Natalia Manetti, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|September 10, 2019
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Pageof 7